BioAge Labs (BIOA) Corporate presentation summary

Platform and strategy

• Focuses on developing therapies for cardiometabolic diseases by leveraging human aging biology and a proprietary discovery platform with over 150 million molecular data points and 50+ years of longitudinal data.

• Validated through ongoing partnerships with Novartis and Lilly for drug and target discovery in metabolic aging.

• Board and leadership team includes experienced executives and scientists with extensive biopharma backgrounds and a track record of clinical and regulatory success.

Lead program: BGE-102 (NLRP3 inhibitor)

• BGE-102 is an oral, brain-penetrant NLRP3 inhibitor with a unique, patented binding site and novel mechanism, targeting both CNS and peripheral inflammation.

• Demonstrated best-in-class potency in Phase 1, achieving ≥90% IL-1β suppression and 86% hsCRP reduction in obese subjects, with 87–93% achieving normalized hsCRP (<2 mg/L).

• Safety profile shows only mild/moderate, self-limited adverse events, no dose dependency, and a strong safety margin.

• Strong intellectual property position with composition of matter protection through 2045.

Phase 1 clinical results

• Phase 1 included single and multiple ascending dose cohorts in healthy volunteers and obese subjects with elevated hsCRP.

• Dose-proportional pharmacokinetics, CNS penetration at 60 mg and above, and sustained pharmacodynamic effects observed.

• Both 60 mg and 120 mg doses led to 86% reductions in hsCRP and comparable reductions in IL-6 and fibrinogen.

• 87–93% of treated subjects achieved normalized hsCRP; similar efficacy across both dose levels.